 Shares of Vaccinex Inc. soared toward a record rally on record volume Friday, after the biotechnology company announced the signing of multiple-project deals with two prominent pharmaceutical companies. The collaborations will focus on the use of Vaccinexs antibody discovery and novel viral display platform, ActivMAb, for antibody discovery. 